N(alpha)-tosyl-L-phenylalanine chloromethyl ketone induces caspase-dependent apoptosis in transformed human B cell lines with transcriptional down-regulation of anti-apoptotic HS1-associated protein X-1.
N(alpha)-tosyl-L-phenylalanine chloromethylketone (TPCK) has been widely used to investigate signal transduction pathways that are involved in gene expression and cell survival/cell death. However, contradictory effects of TPCK on apoptosis have been reported, and the underlying signaling events leading to TPCK-induced promotion or prevention of apoptosis are not fully understood. Here, we show that TPCK induces caspase-dependent apoptosis in Epstein-Barr virus (EBV)-transformed human B cell lines with release of pro-apoptotic proteins from mitochondria. TPCK treatment also results in down-regulation of the anti-apoptotic proteins, cIAP1, cIAP2, and HAX-1, and caspase-dependent cleavage of the anti-apoptotic proteins, Bcl-2 and XIAP. Quantitative PCR analysis confirmed that the TPCK-induced down-regulation of HAX-1 occurred at the transcriptional level, and experiments using the specific pharmacological inhibitor, Bay 11-7082, suggested that HAX-1 expression is subject to regulation by the transcription factor, NF-kappaB. B cell lines derived from patients with homozygous HAX1 mutations were more sensitive to TPCK-induced apoptosis when compared with normal donor cell lines. Furthermore, N-acetylcysteine effectively blocked TPCK-induced apoptosis in EBV-transformed B cell lines and prevented the down-regulation or cleavage of anti-apoptotic proteins. Taken together, our studies demonstrate that TPCK induces apoptosis in human B cell lines and exerts multiple effects on pro- and anti-apoptotic factors.
Jitkaew
Siriporn
S
Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm 171 76, Sweden; Department of Biochemistry, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand; Thalassemia Research Center, Institute of Science and Technology for Research and Development, Mahidol University, Nakhonpathom 73170, Thailand.
Trebinska
Alicja
A
Department of Molecular Biology, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw 02-781, Poland.
Grzybowska
Ewa
E
Department of Molecular Biology, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw 02-781, Poland.
Carlsson
Göran
G
Childhood Cancer Research Unit, Department of Woman and Child Health, Karolinska Institutet, Karolinska University Hospital, Stockholm 171 76, Sweden.
Nordström
Anders
A
Karolinska Biomics Center, Department of Oncology and Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm 171 76, Sweden.
Lehtiö
Janne
J
Karolinska Biomics Center, Department of Oncology and Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm 171 76, Sweden.
Fröjmark
Anne-Sophie
AS
Department of Genetics and Pathology, The Rudbeck Laboratory, Uppsala University, 751 85 Uppsala, Sweden.
Dahl
Niklas
N
Department of Genetics and Pathology, The Rudbeck Laboratory, Uppsala University, 751 85 Uppsala, Sweden.
Fadeel
Bengt
B
Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm 171 76, Sweden. Electronic address: bengt.fadeel@ki.se.
D000111:Acetylcysteine / Q000378:metabolism; D048868:Adaptor Proteins, Signal Transducing; D000975:Antioxidants / Q000378:metabolism; D017209:Apoptosis / Q000187:drug effects* / Q000502:physiology; D001402:B-Lymphocytes / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D000075747:Baculoviral IAP Repeat-Containing 3 Protein; D020169:Caspases / Q000378:metabolism*; D002461:Cell Line, Transformed; D002471:Cell Transformation, Neoplastic; D003374:Coumarins / Q000378:metabolism; D003545:Cysteine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation / Q000187:drug effects; D005456:Fluorescent Dyes / Q000378:metabolism; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000378:metabolism; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics / Q000378:metabolism; D019169:Jurkat Cells; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism; D009842:Oligopeptides / Q000378:metabolism; D011065:Poly(ADP-ribose) Polymerases / Q000235:genetics / Q000378:metabolism; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology*; D011506:Proteins / Q000235:genetics / Q000378:metabolism*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism; D014108:Tosylphenylalanyl Chloromethyl Ketone / Q000494:pharmacology*; D014158:Transcription, Genetic / Q000187:drug effects*; D044767:Ubiquitin-Protein Ligases; D051636:X-Linked Inhibitor of Apoptosis Protein / Q000235:genetics / Q000378:metabolism
D048868:Adaptor Proteins, Signal Transducing; D000975:Antioxidants; D003374:Coumarins; D005456:Fluorescent Dyes; C104759:HAX1 protein, human; D051034:Inhibitor of Apoptosis Proteins; D016328:NF-kappa B; D009842:Oligopeptides; D011500:Protein Synthesis Inhibitors; D011506:Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D017382:Reactive Oxygen Species; D051636:X-Linked Inhibitor of Apoptosis Protein; C496866:XIAP protein, human; C102580:acetyl-aspartyl-glutamyl-valyl-aspartyl-amino-4-methylcoumarin; D014108:Tosylphenylalanyl Chloromethyl Ketone; C494833:BIRC2 protein, human; C494832:BIRC3 protein, human; D000075747:Baculoviral IAP Repeat-Containing 3 Protein; D044767:Ubiquitin-Protein Ligases; D011065:Poly(ADP-ribose) Polymerases; D020169:Caspases; D003545:Cysteine; D000111:Acetylcysteine
Nature. 2008 Mar 6;452(7183):98-102
18288109
J Intern Med. 2008 Oct;264(4):388-400
18513342
J Immunol. 1997 Mar 15;158(6):2736-44
9058808
Nat Genet. 2007 Jan;39(1):86-92
17187068
Cancer Res. 2001 Nov 1;61(21):7777-84
11691792
Biochem Biophys Res Commun. 2003 Jul 11;306(4):954-8
12821135
Biochemistry. 1963 Mar-Apr;2:252-5
13992248
Nucleic Acids Res. 1996 Jan 1;24(1):238-41
8594589
In Silico Biol. 2002;2(1):S1-15
11808873
Cell Death Differ. 1999 Apr;6(4):342-50
10381628
J Virol. 2002 Jan;76(2):802-16
11752170
J Cell Biochem. 2008 Apr 1;103(5):1646-56
17879947
Science. 1997 Feb 21;275(5303):1132-6
9027315
Science. 1997 Dec 12;278(5345):1966-8
9395403
J Biol Chem. 1999 Jul 23;274(30):21155-61
10409669
J Biol Chem. 2004 Nov 26;279(48):50295-301
15371414
Cell Cycle. 2004 Dec;3(12):1566-71
15539954
Cell Death Differ. 1997 Oct;4(7):590-9
14555972
Blood. 2005 May 15;105(10):4070-7
15692060
J Mol Biol. 2008 Jun 13;379(4):645-55
18472110
EMBO J. 1999 Oct 1;18(19):5242-51
10508158
J Biol Chem. 2001 Apr 13;276(15):12466-75
11278584
Gene. 2006 Apr 12;371(1):84-92
16516414
Cancer Biol Ther. 2004 Aug;3(8):761-8
15197350
Leukemia. 1999 May;13(5):719-28
10374876
Mol Cell Biol. 1996 Sep;16(9):5015-25
8756660
Hepatology. 1998 Jun;27(6):1632-42
9620337
Hum Genet. 1986 Aug;73(4):320-6
3017841
Circ Res. 2006 Aug 18;99(4):415-23
16857965
Blood. 2004 May 1;103(9):3355-61
14764541
EMBO J. 1996 Sep 2;15(17):4682-90
8887559
Cell Death Differ. 1998 Nov;5(11):953-62
9846182